Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK3 R172Q||Advanced Solid Tumor||sensitive||JAK Inhibitor (Pan) - ATP competitive||Tofacitinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed human cells expressing JAK3 R172Q in culture demonstrated decreased cell survival, reduced phosphorylation of Stat5a, and G1 arrest when treated with Xeljanz (tofacitinib) (PMID: 21821710).||21821710|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|